Clinical trials
Lung Cancer (Suspected or Confirmed) clinical trials
Below are recruiting lung cancer (suspected or confirmed) clinical trials, each written for real people, not researchers. We’re tracking 6,575 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07091305RecruitingPhase 2
Study of a new drug with chemotherapy for limited-stage small cell lung cancer
This trial tests an investigational drug called QL1706 combined with chemotherapy, given after standard chemoradiation, for people with limited-stage small cell lung cancer. The goal is to see if this combination helps keep the cancer from coming back.
ShanghaiAges 18–75 - NCT07086456RecruitingPhase 2
Combination therapy for advanced lung cancer
This trial tests a combination of chemotherapy, radiation, and two targeted drugs (surufatinib and tislelizumab) for people with stage III non-small cell lung cancer that cannot be surgically removed. The goal is to see if this approach works better than standard treatment.
Guangzhou, GuangdongAges 18–75 - NCT07076836Recruiting
Electroacupuncture for lung cancer patients on immunotherapy
This study tests whether adding electroacupuncture at a specific point on the leg (called Zusanli) can help people with lung cancer who are getting chemotherapy and immunotherapy before surgery. It might reduce side effects and improve response to treatment.
Chengdu, SichuanAges 18–80 - NCT07084610RecruitingPhase 2
Metabolic markers predict response to immunotherapy before lung cancer surgery
This trial tests whether certain markers in your blood or tissue can predict how well immunotherapy works before surgery for early-stage lung cancer. It aims to find out who benefits most from this treatment.
Ribeirão Preto, São PauloAges 18 years+ - NCT06659042RecruitingPhase 2
Tislelizumab before and after surgery for KRAS-mutated lung cancer
This trial tests whether adding the immunotherapy drug tislelizumab before and after surgery can help people with a specific type of lung cancer (non-squamous NSCLC with a KRAS mutation) that is stage 2 or 3. It aims to improve treatment outcomes by targeting the cancer early.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07066813Recruiting
Lung cancer with air pockets: staging and treatment
This study looks at lung cancers that have air-filled spaces inside them. It explores how the stage of the cancer affects treatment outcomes. If you have this type of lung cancer and have had surgery, this trial may help doctors learn more about your condition.
Changsha, HunanAges Any age - NCT07063745RecruitingPhase 2/Phase 3
Comparing a new drug combo for advanced lung cancer with a specific gene change
This trial tests a new drug called Navlimetostat combined with pembrolizumab and chemotherapy versus a placebo with the same standard treatments. It is for people with metastatic non-small cell lung cancer that has a specific missing gene (MTAP deletion) and who have not had prior treatment for their advanced disease.
Anchorage, AlaskaAges 18 years+ - NCT07056556RecruitingPhase 1
Study of BL-M09D1 for advanced lung and other solid tumors
This trial tests a new drug, BL-M09D1, in people with advanced non-small cell lung cancer or other solid tumors that have not responded to standard treatments. The goal is to see if the drug can help shrink or control the cancer.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07057791RecruitingPhase 2
Chemo plus immunotherapy for extensive-stage small cell lung cancer
This trial tests a combination of chemotherapy (platinum/etoposide) plus an immunotherapy drug (ivonescimab) for people with extensive-stage small cell lung cancer who have not received treatment before. The goal is to see if adding the immunotherapy improves outcomes.
Miami, FloridaAges 18 years+ - NCT07046923RecruitingPhase 1
A study of LY4175408 for advanced cancer
This trial tests a new targeted drug (LY4175408) for people with certain advanced solid tumors (lung, endometrial, or triple negative breast cancer) who have already tried standard treatments. The goal is to see if the drug is safe and effective.
Stanford, CaliforniaAges 18 years+ - NCT06429696RecruitingPhase 2
Maintenance therapy for extensive stage small cell lung cancer
This study tests if a combination of an immunotherapy drug (PD-L1 inhibitor) and a targeted therapy pill (apatinib) can help keep extensive stage small cell lung cancer from growing after initial treatment. It is for people whose cancer was controlled with first-line chemo-immunotherapy.
Guangzhou, GuangdongAges 18–75 - NCT07038096RecruitingPhase 1/Phase 2
Testing ZG006 and ZG005 for lung and neuroendocrine cancers
This trial tests two new drugs, ZG006 and ZG005, for people with advanced small cell lung cancer or neuroendocrine carcinoma. The goal is to see if these drugs can shrink tumors or slow cancer growth.
Guanzhou, GuangdongAges 18–70 - NCT07037758RecruitingPhase 1
Study of tarlatamab and AB248 for extensive stage small cell lung cancer
This trial tests a new combination of two drugs, tarlatamab and AB248, for people with extensive stage small cell lung cancer that has worsened after at least one prior treatment. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
Gilbert, ArizonaAges 18–90 - NCT07041320Recruiting
Oral chemo and immunotherapy for older adults with lung cancer
This trial is testing a combination of an oral chemotherapy pill (vinorelbine) and an immunotherapy drug (PD-1 inhibitor) for people aged 65 and older with advanced non-small cell lung cancer who have not had treatment before. The goal is to see if this approach can help control the cancer with fewer side effects.
Hefei, AnhuiAges 65 years+ - NCT07034391RecruitingPhase 2
PD-1 inhibitor with denosumab and chemo for advanced lung cancer
This trial tests a combination of an immunotherapy drug (PD-1 inhibitor), a bone-strengthening drug (denosumab), and chemotherapy for people with advanced or spread non-squamous non-small cell lung cancer that does not have certain genetic changes. The goal is to see if this combination helps shrink tumors and control the disease.
Shenyang, LiaoningAges 18–75 - NCT06992583RecruitingPhase 1
CAR-T cell therapy for advanced CEA-positive lung cancer
This trial tests a new type of immune therapy called CAR-T cells that are designed to attack lung cancer cells with a specific marker called CEA. It may be an option for people with advanced lung cancer who have already tried other treatments.
Nanjing, JiangsuAges 18 years+ - NCT06598527RecruitingPhase 3
Radiation and immunotherapy before surgery for lung cancer
This trial tests adding targeted radiation before standard immunotherapy and chemotherapy for people with stage 2-3 non-small cell lung cancer that can be surgically removed. The goal is to see if the radiation helps shrink the tumor more before surgery.
Guangzhou, GuangdongAges 18–75 - NCT07028489Recruiting
Studying a standard-care comparison group for advanced EGFR-mutant lung cancer
This trial collects information from people with a specific type of advanced lung cancer to create a comparison group. It helps researchers understand how well new treatments work without giving any experimental medicine.
Monterey, CaliforniaAges 18 years+ - NCT07027514RecruitingPhase 1
Combination treatment for advanced lung cancer
This study tests a new drug called tolododekin alfa combined with an approved immunotherapy drug for people with advanced non-small cell lung cancer. The goal is to see if this combination is safe and effective.
Coral Gables, FloridaAges 18 years+ - NCT07023068Enrolling by invitationEarly Phase 1
68Ga-DPA scan for lung cancer diagnosis
This trial tests a new imaging agent called 68Ga-DPA to see if it can help find and measure lung cancer tumors. It is for people who are suspected or confirmed to have lung cancer and need a biopsy or surgery soon.
BeijingAges 18–85 - NCT07010263RecruitingPhase 3
AK112 for limited-stage small cell lung cancer after chemoradiation
This study tests a new drug called AK112 (a bispecific antibody that blocks both PD-1 and VEGF) as a consolidation treatment to help prevent your limited-stage small cell lung cancer from coming back after you've finished chemoradiation. It's for people whose cancer has not grown following concurrent chemotherapy and radiation.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07005102RecruitingPhase 2/Phase 3
Telisotuzumab adizutecan and osimertinib for EGFR-positive lung cancer
This trial tests a new drug combination (telisotuzumab adizutecan plus osimertinib) as a first treatment for adults with a specific type of advanced lung cancer that has an EGFR mutation. The goal is to see if the combination is safe and works better than standard care.
Chandler, ArizonaAges 18 years+ - NCT06996782RecruitingPhase 1/Phase 2
Lung cancer study testing new combination treatments
This study tests a new drug (rilvegostomig) alone or with chemotherapy or another drug (ramucirumab) for advanced non-small cell lung cancer that has spread. It aims to see if these combinations work better than standard treatments.
Phoenix, ArizonaAges 18 years+ - NCT06945523RecruitingPhase 1
CAR-T cell therapy for CEA-positive advanced lung cancer
This trial tests a treatment using your own immune cells, modified to target a protein called CEA on lung cancer cells. It's for people with advanced lung cancer that has gotten worse after at least one prior treatment.
Wuhan, HubeiAges 18 years+
Hear when a new Lung Cancer (Suspected or Confirmed) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for lung cancer (suspected or confirmed)?
- Yes. Clin2 currently lists 6,575 recruiting lung cancer (suspected or confirmed) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a lung cancer (suspected or confirmed) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a lung cancer (suspected or confirmed) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.